Results: 2

1.
Figure 2  

Figure 2  . From: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Kaplan-Meier survival analysis. (A) Cohort of patients with hepatorenal syndrome (HRS) treated by transjugular intrahepatic portosystemic stent-shunt (TIPS) (n=31); (B) survival analysis after TIPS according to HRS subtypes at baseline; (C) survival analysis according to clinical response (improved sodium excretion and ascites control within one month) or no response after TIPS; (D) survival analysis of non-TIPS patients (n=10: type I HRS, n=7; type II HRS, n=3) receiving the best medical support. p values were derived from subgroup comparisons using the log rank test.

K Brensing, et al. Gut. 2000 August;47(2):288-295.
2.
Figure 1  

Figure 1  . From: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Mean (SD) serum creatinine levels (mg/dl; to convert values to µmol/l multiply by 88.4), creatinine clearance (ml/min), and sodium excretion (mmol/24 hours) up to one year after diagnosis of hepatorenal syndrome in 41 patients of whom 31 received a transjugular intrahepatic portosystemic stent-shunt (TIPS) and 10 were excluded from receiving TIPS. p values were calculated using the Mann-Whitney U test and represent comparisons with baseline for patients at risk or between treatment groups at given time intervals: *p<0.05, **p<0.01, ***p<0.001. Note that all values prior to and up to one week after TIPS were determined without diuretics. Thereafter, moderate diuretic medication with furosemide (40-80 mg/day) and spironolactone (100-200 mg/day) was reintroduced and adapted to the patients' needs.

K Brensing, et al. Gut. 2000 August;47(2):288-295.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk